Neurocrine Biosciences is a biopharmaceutical company dedicated to developing innovative treatments for neurological, neuroendocrine, and neuropsychiatric disorders. With over three decades of experience, the company focuses on addressing unmet clinical needs through a robust pipeline of investigational therapies. Their research spans various areas, including movement disorders, pediatric epilepsies, and rare endocrine conditions. Notable investigational products include valbenazine, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor aimed at treating dyskinetic cerebral palsy, and NBI-921352, a sodium channel inhibitor for SCN8A developmental and epileptic encephalopathy. These therapies are currently in various phases of clinical trials, reflecting the company's commitment to precision medicine and targeted treatment approaches.

In addition to their neurology-focused pipeline, Neurocrine is also advancing therapies in neuroendocrinology and neuropsychiatry. For instance, crinecerfont is being developed as a selective corticotropin-releasing factor type 1 (CRF1) receptor antagonist for congenital adrenal hyperplasia, while NBI-1065845 and NBI-1117568 are investigational treatments targeting major depressive disorder and schizophrenia, respectively. The company actively collaborates with other organizations, such as AbbVie and Voyager Therapeutics, to enhance their research capabilities and expand their therapeutic offerings. Through these efforts, Neurocrine Biosciences aims to provide life-changing solutions for patients facing significant health challenges.

United States

Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, Neurocrine Biosciences has specialized in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit neurocrine.com. (*in collaboration with AbbVie)


Central Nervous System (CNS)

Endocrine System Diseases

Genetic Diseases

Psychological Diseases

Urogenital Diseases

Neurocrine Biosciences

Congenital adrenal hyperplasia

Crinecerfont is an investigational, oral, non-steroidal corticotropin-releasing factor type 1 (CRF1) receptor antagonist under evaluation for the treatment of classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD). The blockade of CRF receptors in the pituitary has been shown to decrease the release of adrenocorticotropic hormone (ACTH), which in turn decreases the production of adrenal androgens, and potentially the symptoms associated with classic CAH. Adding crinecerfont treatment to glucocorticoid therapy has the potential to reduce the adverse consequences of androgen excess and of long-term exposure to greater than replacement doses of glucocorticoids, enabling patients to better manage the symptoms of classic CAH.
To learn more about crinecerfont, click <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3103440-1&amp;h=2246733495&amp;u=https%3A%2F%2Fwww.neurocrine.com%2Fpipeline%2Fcongenital-adrenal-hyperplasia%2Fnbi-74788%2F&amp;a=here" rel="nofollow" target="_blank">here</a>.

CRENESSITY™ (crinecerfont) [capsule]

Dyskinesia

Huntington's disease

Valbenazine, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, is thought to work by reducing the amount of dopamine released in a region of the brain that controls movement and motor function. VMAT2 is a protein in the brain that packages neurotransmitters, such as dopamine, for transport and release in presynaptic neurons. Valbenazine is novel in that it selectively inhibits VMAT2 with no appreciable binding affinity for VMAT1, dopaminergic (including D2), serotonergic, adrenergic, histaminergic or muscarinic receptors. Valbenazine is currently FDA-approved for the treatment of adults with tardive dyskinesia, an irreversible involuntary movement disorder, and may show similar benefits in addressing the motor symptoms associated with chorea in patients with Huntington disease.

INGREZZA (valbenazine) 

Chorea

Valbenazine, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, is thought to work by reducing the amount of dopamine released in a region of the brain that controls movement and motor function. VMAT2 is a protein in the brain that packages neurotransmitters, such as dopamine, for transport and release in presynaptic neurons. Valbenazine is novel in that it selectively inhibits VMAT2 with no appreciable binding affinity for VMAT1, dopaminergic (including D2), serotonergic, adrenergic, histaminergic or muscarinic receptors.

INGREZZA (valbenazine)

CRENESSITY™ (crinecerfont) [oral solution]

Cerebral Palsy

Neurological disorder

Valbenazine, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, is thought to work by reducing the amount of dopamine released in a region of the brain that controls movement and motor function. VMAT2 is a protein in the brain that packages neurotransmitters, such as dopamine, for transport and release in presynaptic neurons. Valbenazine is novel in that it selectively inhibits VMAT2 with no appreciable binding affinity for VMAT1, dopaminergic (including D2), serotonergic, adrenergic, histaminergic or muscarinic receptors.

Valbenazine

Psychiatric disorder

Schizophrenia

Valbenazine 

Major depressive disorder

Osavampator (NBI-1065845/TAK-653)

NBI-1117568 

Focal Onset Seizures

NBI-921352

NBI-1070770

EFMODY is a modified-release preparation of hydrocortisone that mimics the physiological circadian rhythm of cortisol and has been specifically designed for patients with diseases of cortisol deficiency, such as CAH and adrenal insufficiency.

Efmody

Adrenal Insufficiency

Chronocort® (Efmody)

NBI-1117570 is an investigational, oral, muscarinic M1/M4 dual agonist. Muscarinic receptors are fundamental to activating signaling pathways in the brain. There are five muscarinic acetylcholine receptors involved in neurotransmission, two of which are selectively targeted by NBI-1117570 (M1 and M4), with M1 validated as a potential drug target in cognition and M4 in psychosis for clinical drug development. Neurocrine Biosciences acquired the rights to develop and commercialize NBI-1117570 from Sosei Heptares.

NBI-1117570

NBI-1065890

NBI-1117567 is an investigational, oral, M1/M4 (M1 preferring) selective muscarinic agonist. Muscarinic receptors are fundamental to activating signaling pathways in the brain. There are five muscarinic acetylcholine receptors involved in neurotransmission, two of which are selectively targeted by NBI-1117567 (M1 preferring and M4), with M1 validated as a potential drug target in cognition and M4 in psychosis. Neurocrine Biosciences acquired the rights to develop and commercialize NBI-1117567 from Nxera Pharma (formerly Sosei Heptares).

NBI-1117567

Dystonia (Blepharospasm)

Parkinson's disease

Identified and developed by Neurocrine Biosciences, NBI-1076986 is an investigational, oral, M4 subtype-selective muscarinic acetylcholine receptor antagonist for the potential treatment of certain movement disorders, including Parkinson's disease tremor and dystonia. It is hypothesized that an M4 subtype-selective antagonist may impact regulation of motor symptoms and movements while minimizing off-target effects.

Neurocrine Biosciences

Company Details